Cargando…

The effectiveness of low-dose desmopressin in improving hypothermia-induced impairment of primary haemostasis under influence of aspirin – a randomized controlled trial

BACKGROUND: Mild hypothermia (34–35 °C) increases perioperative blood loss. Our previous studies showed that desmopressin could have in vitro beneficial effects on hypothermia-induced primary haemostasis impairment. In this study, we investigate the in vitro effects of desmopressin on hypothermia-in...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsui, Pui Yee, Cheung, Chi Wai, Lee, Yvonne, Leung, Susan Wai Sum, Ng, Kwok Fu Jacobus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4469427/
https://www.ncbi.nlm.nih.gov/pubmed/26017715
http://dx.doi.org/10.1186/s12871-015-0061-5
_version_ 1782376623560982528
author Tsui, Pui Yee
Cheung, Chi Wai
Lee, Yvonne
Leung, Susan Wai Sum
Ng, Kwok Fu Jacobus
author_facet Tsui, Pui Yee
Cheung, Chi Wai
Lee, Yvonne
Leung, Susan Wai Sum
Ng, Kwok Fu Jacobus
author_sort Tsui, Pui Yee
collection PubMed
description BACKGROUND: Mild hypothermia (34–35 °C) increases perioperative blood loss. Our previous studies showed that desmopressin could have in vitro beneficial effects on hypothermia-induced primary haemostasis impairment. In this study, we investigate the in vitro effects of desmopressin on hypothermia-induced primary haemostasis impairment under the influence of aspirin in healthy volunteers. METHODS: Sixty healthy volunteers were randomly allocated to taking aspirin 100 mg or placebo for three days. On the sixth day blood samples were taken before and after the injection of desmopressin (1.5 microgram or 5 microgram) or normal saline subcutaneously. Measurements including Platelet Function Analyzer (PFA-100®) closure times, plasma von Willebrand Factor antigen, haemoglobin and platelet levels were made at 32 °C and 37 °C respectively. RESULTS: Collagen/epinephrine closure time (EPICT) was significantly prolonged by 21.13 % (95 %CI 2.34–39.74 %, p = 0.021) in aspirin group at 37 °C. While hypothermia alone prolonged both collagen/adenosine diphosphate (ADPCT) and EPICT by 17.63 % (95 %CI 13.5–20.85 %, p < 0.001) and 8.0 % (95 %CI 6.38–10.04 %, p = 0.024) respectively, addition of aspirin only further prolonged EPICT by 19.9 % (95 %CI 3.32–36.49 %, p = 0.013). In aspirin group, desmopressin 1.5 microgram and 5 microgram significantly reduced ADPCT to below baseline levels at 37 °C (p = 0.025 and <0.001 respectively), whereas reduction in EPICT was seen with desmopressin 5 microgram (p =0.008). The effect was less pronounced at 32 °C, with a significant reduction in EPICT obtained with a dosage of 5 microgram only (p = 0.011). CONCLUSION: It was shown that aspirin could further potentiate the hypothermia-induced closure time prolongations. Low dose desmopressin (1.5 microgram) reduced PFA-100® closure times towards baseline. A higher dosage (5 microgram) further reduced the closure times below baseline. Therefore low dose desmopressin (1.5 microgram) might have the potential to correct hypothermia-induced primary haemostasis impairment under the influence of aspirin during the perioperative period. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01382134
format Online
Article
Text
id pubmed-4469427
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44694272015-06-18 The effectiveness of low-dose desmopressin in improving hypothermia-induced impairment of primary haemostasis under influence of aspirin – a randomized controlled trial Tsui, Pui Yee Cheung, Chi Wai Lee, Yvonne Leung, Susan Wai Sum Ng, Kwok Fu Jacobus BMC Anesthesiol Research Article BACKGROUND: Mild hypothermia (34–35 °C) increases perioperative blood loss. Our previous studies showed that desmopressin could have in vitro beneficial effects on hypothermia-induced primary haemostasis impairment. In this study, we investigate the in vitro effects of desmopressin on hypothermia-induced primary haemostasis impairment under the influence of aspirin in healthy volunteers. METHODS: Sixty healthy volunteers were randomly allocated to taking aspirin 100 mg or placebo for three days. On the sixth day blood samples were taken before and after the injection of desmopressin (1.5 microgram or 5 microgram) or normal saline subcutaneously. Measurements including Platelet Function Analyzer (PFA-100®) closure times, plasma von Willebrand Factor antigen, haemoglobin and platelet levels were made at 32 °C and 37 °C respectively. RESULTS: Collagen/epinephrine closure time (EPICT) was significantly prolonged by 21.13 % (95 %CI 2.34–39.74 %, p = 0.021) in aspirin group at 37 °C. While hypothermia alone prolonged both collagen/adenosine diphosphate (ADPCT) and EPICT by 17.63 % (95 %CI 13.5–20.85 %, p < 0.001) and 8.0 % (95 %CI 6.38–10.04 %, p = 0.024) respectively, addition of aspirin only further prolonged EPICT by 19.9 % (95 %CI 3.32–36.49 %, p = 0.013). In aspirin group, desmopressin 1.5 microgram and 5 microgram significantly reduced ADPCT to below baseline levels at 37 °C (p = 0.025 and <0.001 respectively), whereas reduction in EPICT was seen with desmopressin 5 microgram (p =0.008). The effect was less pronounced at 32 °C, with a significant reduction in EPICT obtained with a dosage of 5 microgram only (p = 0.011). CONCLUSION: It was shown that aspirin could further potentiate the hypothermia-induced closure time prolongations. Low dose desmopressin (1.5 microgram) reduced PFA-100® closure times towards baseline. A higher dosage (5 microgram) further reduced the closure times below baseline. Therefore low dose desmopressin (1.5 microgram) might have the potential to correct hypothermia-induced primary haemostasis impairment under the influence of aspirin during the perioperative period. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01382134 BioMed Central 2015-05-28 /pmc/articles/PMC4469427/ /pubmed/26017715 http://dx.doi.org/10.1186/s12871-015-0061-5 Text en © Tsui et al. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Tsui, Pui Yee
Cheung, Chi Wai
Lee, Yvonne
Leung, Susan Wai Sum
Ng, Kwok Fu Jacobus
The effectiveness of low-dose desmopressin in improving hypothermia-induced impairment of primary haemostasis under influence of aspirin – a randomized controlled trial
title The effectiveness of low-dose desmopressin in improving hypothermia-induced impairment of primary haemostasis under influence of aspirin – a randomized controlled trial
title_full The effectiveness of low-dose desmopressin in improving hypothermia-induced impairment of primary haemostasis under influence of aspirin – a randomized controlled trial
title_fullStr The effectiveness of low-dose desmopressin in improving hypothermia-induced impairment of primary haemostasis under influence of aspirin – a randomized controlled trial
title_full_unstemmed The effectiveness of low-dose desmopressin in improving hypothermia-induced impairment of primary haemostasis under influence of aspirin – a randomized controlled trial
title_short The effectiveness of low-dose desmopressin in improving hypothermia-induced impairment of primary haemostasis under influence of aspirin – a randomized controlled trial
title_sort effectiveness of low-dose desmopressin in improving hypothermia-induced impairment of primary haemostasis under influence of aspirin – a randomized controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4469427/
https://www.ncbi.nlm.nih.gov/pubmed/26017715
http://dx.doi.org/10.1186/s12871-015-0061-5
work_keys_str_mv AT tsuipuiyee theeffectivenessoflowdosedesmopressininimprovinghypothermiainducedimpairmentofprimaryhaemostasisunderinfluenceofaspirinarandomizedcontrolledtrial
AT cheungchiwai theeffectivenessoflowdosedesmopressininimprovinghypothermiainducedimpairmentofprimaryhaemostasisunderinfluenceofaspirinarandomizedcontrolledtrial
AT leeyvonne theeffectivenessoflowdosedesmopressininimprovinghypothermiainducedimpairmentofprimaryhaemostasisunderinfluenceofaspirinarandomizedcontrolledtrial
AT leungsusanwaisum theeffectivenessoflowdosedesmopressininimprovinghypothermiainducedimpairmentofprimaryhaemostasisunderinfluenceofaspirinarandomizedcontrolledtrial
AT ngkwokfujacobus theeffectivenessoflowdosedesmopressininimprovinghypothermiainducedimpairmentofprimaryhaemostasisunderinfluenceofaspirinarandomizedcontrolledtrial
AT tsuipuiyee effectivenessoflowdosedesmopressininimprovinghypothermiainducedimpairmentofprimaryhaemostasisunderinfluenceofaspirinarandomizedcontrolledtrial
AT cheungchiwai effectivenessoflowdosedesmopressininimprovinghypothermiainducedimpairmentofprimaryhaemostasisunderinfluenceofaspirinarandomizedcontrolledtrial
AT leeyvonne effectivenessoflowdosedesmopressininimprovinghypothermiainducedimpairmentofprimaryhaemostasisunderinfluenceofaspirinarandomizedcontrolledtrial
AT leungsusanwaisum effectivenessoflowdosedesmopressininimprovinghypothermiainducedimpairmentofprimaryhaemostasisunderinfluenceofaspirinarandomizedcontrolledtrial
AT ngkwokfujacobus effectivenessoflowdosedesmopressininimprovinghypothermiainducedimpairmentofprimaryhaemostasisunderinfluenceofaspirinarandomizedcontrolledtrial